Judith Fafard

Judith Fafard

Auto-generated profile, based on publicly available information

Judith Fafard

Laboratoire de santé publique du Québec, Institut national de santé publique du Québec

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Cell Reports
Verified
Journal Article
Open access
ATAlexandra Tauzin
Alexandra Tauzin
SGShang Yu Gong
Shang Yu Gong
DCDebashree Chatterjee
Debashree Chatterjee
SDShilei Ding
Shilei Ding
MPMark M. Painter
Mark M. Painter
AFAndrés Finzi
Andrés Finzi
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.

1 January 2023 in Annals of Internal Medicine
Verified
Journal Article
Open access
LHLuke B. Harrison
Luke B. Harrison
GBGeneviève Bergeron
Geneviève Bergeron
GCGeneviève Cadieux
Geneviève Cadieux
HCHugues Charest
Hugues Charest
JFJudith Fafard
Judith Fafard
SBSapha Barkati
Sapha Barkati
A global outbreak of monkeypox occurred beginning in mid-2022 outside of endemic areas. This report characterizes the outbreak of monkeypox in Montréal, the first large outbreak in North America, u... Visual Monkeypox in Montréal. A global outbreak of monkeypox occurred beginning in mid-2022 outside of endemic areas. This report characterizes the outbreak of monkeypox in Montréal, the f... Background: Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas. Objective: To characterize the outbreak of monkeypox in Montréal, the first large outbreak in...

4 June 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
IBIsabelle Bernaquez
Isabelle Bernaquez
JDJeannot Dumaresq
Jeannot Dumaresq
IPIsabelle Picard
Isabelle Picard
CGColette Gaulin
Colette Gaulin
RDRéjean Dion
Réjean Dion
SBSadjia Bekal
Sadjia Bekal
Background Salmonella enterica serovar 4,[5],12:i:- (S. 4,[5],12:i:-), the monophasic variant of Typhimurium, is among the most prevalent surface antigen subtypes and most frequent carriers of multidrug-resistance in Salmonella worldwide, therefore becoming a prominent public health threat. Methods Genomic surveillance data analysis, in addition to human case and animal health investigations and food inspections from Quebec, Canada were conducted to identify the source of an emerging S. 4,[5],12:i:- cluster from 2021–2023. We performed antimicrobial susceptibility testing, whole genome sequencing, phylogeny and comparative genomic analyses to characterize this local strain. Results We show that a cluster of 41 S. 4,[5],12:i:- emerged in Quebec, Canada, after acquiring a self-conjugative IncHI2A plasmid encoding extensive drug-resistance (mph(A), blaCTX-M-55, qnrS1) and potential reduced biocide susceptibility via efflux pump regulators (ramAp, marR), metal resistance (terZABCDE, copG) and oxidative stress responses (umuDC, dsbC), among other mechanisms. Genomic epidemiology identifies 20 human cases, 16 veal calves, 3 dogs, one piglet, one moose, and 4 raw meat-based diet isolates belonging to this cluster. Infants are mainly (50%) affected, and dogs fed raw meat-based diets are the major source identified, followed by exposure to cattle. Retrospective genomic analyses demonstrates its association to USA porcine and shared plasmid pool among many food-producing animals, but indicated different niches for different plasmid subtypes. Conclusions This study highlights the threat of S. 4,[5],12:i:- ST34 and its raw pet food-based transmission to vulnerable human populations, where impacted veal farms and asymptomatic dogs can act as disease carriers with limited treatment options and possible environmental persistence.

2 October 2021 in Journal of Clinical Virology
Verified
Journal Article
Closed access
JDJeannot Dumaresq
Jeannot Dumaresq
FCFrancois Coutlee
Francois Coutlee
PDPhilippe J. Dufresne
Philippe J. Dufresne
JLJean Longtin
Jean Longtin
JFJudith Fafard
Judith Fafard
ALAnnie-Claude Labbé
Annie-Claude Labbé

6 December 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
YLYves Longtin
Yves Longtin
LPLeighanne O. Parkes
Leighanne O. Parkes
HCHugues Charest
Hugues Charest
SRStacy Rajarison
Stacy Rajarison
GZGerasimos J. Zaharatos
Gerasimos J. Zaharatos
GSGaston De Serres
Gaston De Serres
We performed viral culture of nasopharyngeal specimens in individuals aged 79 and older, infected with severe acute respiratory coronavirus virus 2 (SARS-CoV-2), 10 days after symptom onset. A positive viral culture was obtained in 10 (45%) of 22 participants, including 4 (33%) of 12 individuals with improving symptoms. The results of this small study suggest that infectivity may be prolonged among older individuals.

13 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SCSara Carazo
Sara Carazo
DSDanuta M Skowronski
Danuta M Skowronski
NBNicholas Brousseau
Nicholas Brousseau
CGCharles-Antoine Guay
Charles-Antoine Guay
CSChantal Sauvageau
Chantal Sauvageau
GSGaston De Serres
Gaston De Serres
Background. We evaluated mRNA COVID–19 vaccine effectiveness (VE) for the XBB.1.5 formulation against COVID–19 hospitalizations among adults aged ≥60 years during a ten–month follow–up period. Methods. We conducted a test–negative case–control study using Quebec population–based administrative data. Specimens collected from individuals aged ≥60 years tested at an acute–care hospital from October 2023 to August 2024 were considered test–positive cases if hospitalized for COVID–19, or controls if test–negative for SARS–CoV–2. Vaccination was defined by receipt of at least one mRNA XBB–vaccine (autumn or spring) dose. Multivariate logistic regression analyses estimated VE relative to several comparator groups, primarily those last–vaccinated in 2022, by subvariant predominant period (XBB, JN and KP), by time since XBB–vaccination and by number of XBB–vaccine doses (KP period). Results. Participants overall and by XBB, JN and KP periods included: 5532 (4.9%) test–positive cases (1321, 1838 and 1372, respectively) and 108473 (95.1%) test–negative controls (12881, 53414 and 28595, respectively); 14584 specimens were collected during periods of subvariant cocirculation. By subvariant period, 3322 (25.8%), 27041 (50.6%) and 15401 (53.9%) controls, respectively, were considered XBB–vaccinated. Overall VE was 30% (95%CI:24–35) and by XBB, JN or KP period: 54% (95%CI:46–62), 23% (95%CI:13–32) and 0% (95%CI:-18–15), respectively. During each subvariant period, the hospitalization risk was reduced only during the first four months post–vaccination. Conclusions. Among individuals aged ≥60 years, mRNA XBB–vaccination provided meaningful, albeit limited and short–term, protection against COVID–19 hospitalization due to XBB, JN and KP subvariants in. Better vaccines are needed to effectively reduce COVID–19 disease burden.